At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6 enrolled
Drug / intervention
PLX3397drug
Likely dose
PLX3397 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
In Brief
A clinical study evaluating PLX3397 for Melanoma. Completed, enrolled 6 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesChina, South Korea
CollaboratorsDaiichi Sankyo
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartJan 2017
Primary CompletionAug 2018
Study CompletionOct 2024
TodayJul 2026
First PostedNov 29, 2016
Enrollment StartJan 31, 2017
Primary CompletionAug 31, 2018
Study CompletionOct 11, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.6 years ago
Interventions
PLX3397drug
1000 mg/day (400 mg in the morning and 600 mg in the evening)